共 50 条
Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi
被引:20
|作者:
Gopal, Satish
[1
,2
,3
,4
]
Liomba, N. George
[1
]
Montgomery, Nathan D.
[5
]
Moses, Agnes
[1
,4
]
Kaimila, Bongani
[1
]
Nyasosela, Richard
[6
]
Chikasema, Maria
[1
]
Dhungel, Bal M.
[7
]
Kampani, Coxcilly
[1
]
Sanders, Marcia K.
[8
]
Krysiak, Robert
[1
]
Dittmer, Dirk P.
[2
,3
,8
]
Fedoriw, Yuri
[2
,5
]
机构:
[1] UNC Project Malawi, Lilongwe, Malawi
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Program Global Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Med, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA
[4] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi
[5] Univ N Carolina, Div Hematopathol, Dept Pathol & Lab Med, Chapel Hill, NC USA
[6] Kamuzu Cent Hosp, Lilongwe, Malawi
[7] United Nations Dev Program, Lilongwe, Malawi
[8] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA
关键词:
HIV;
multicentric Castleman disease;
Kaposi sarcoma;
Kaposi sarcoma-associated herpesvirus;
non-Hodgkin lymphoma;
sub-Saharan Africa;
HERPESVIRUS;
RITUXIMAB;
LYMPHOMA;
CHEMOTHERAPY;
PATHOLOGY;
AFRICA;
D O I:
10.7448/IAS.18.1.20122
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Introduction: Clinical reports of multicentric Castleman disease (MCD) from sub-Saharan Africa (SSA) are scarce despite high prevalence of HIV and Kaposi sarcoma-associated herpesvirus (KSHV). Our objective is to describe characteristics and survival for HIV-associated MCD patients in Malawi. To our knowledge, this is the first HIV-associated MCD case series from the region. Methods: We describe HIV-positive patients with MCD in Lilongwe, and compare them to HIV-associated lymph node Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) patients treated at our centre. All patients were enrolled into a prospective longitudinal cohort study at a national teaching hospital and cancer referral centre serving half of Malawi's 16 million people. We included adult patients] 18 years of age with HIV-associated MCD (n = 6), lymph node KS (n = 5) or NHL (n = 31) enrolled between 1 June 2013 and 31 January 2015. Results and discussion: MCD patients had a median age of 42.4 years (range 37.2-51.8). All had diffuse lymphadenopathy and five had hepatosplenomegaly. Concurrent KS was present for one MCD patient, and four had performance status >= 3. MCD patients had lower median haemoglobin (6.4 g/dL, range 3.6-9.3) than KS (11.0 g/dL, range 9.1-12.0, p = 0.011) or NHL (11.2 g/dL, range 4.5-15.1, p = 0.0007). Median serum albumin was also lower for MCD (2.1 g/dL, range 1.7-3.2) than KS (3.7 g/dL, range 3.2-3.9, p = 0.013) or NHL (3.4 g/dL, range 1.8-4.8, p = 0.003). All six MCD patients were on antiretroviral therapy (ART) with median CD4 count 208 cells/mu L (range 108-1146), and all with HIV RNA <400 copies/mL. Most KS and NHL patients were also on ART, although ART duration was longer for MCD (56.4 months, range 18.2-105.3) than KS (14.2 months, range 6.8-21.9, p = 0.039) or NHL (13.8 months, range 0.2-98.8, p = 0.017). Survival was poorer for MCD patients than lymph node KS or NHL. Conclusions: HIV-associated MCD occurs in Malawi, is diagnosed late and is associated with high mortality. Improvements in awareness, diagnostic facilities, treatment and supportive care are needed to address this likely under-recognized public health problem in SSA.
引用
收藏
页数:6
相关论文